Aptevo Therapeutics Inc. (APVO) Stock Price & Analysis
Aptevo Therapeutics Inc. (APVO) fell 1.55% to USD 4.76 as of June 10, 2026 at 07:49 UTC, according to Nexqual real-time market data.
APVO last closed at USD 4.84; the session ranged USD 4.6–4.98 on volume of 16,542 shares. Market capitalization is $5.93M, with a 52-week range of USD 3.8–235.98 (NCM). Source: Nexqual, June 10, 2026 at 07:49 UTC.
Key Statistics (as of June 10, 2026 at 07:49 UTC)
| Price | USD 4.76 |
|---|---|
| Change | ▼ 1.55% (down) |
| Previous Close | USD 4.84 |
| Open | USD 4.8 |
| Day Range | USD 4.6 – 4.98 |
| 52-Week Range | USD 3.8 – 235.98 |
| Volume | 16,542 shares |
| Market Cap | $5.93M |
| Exchange | NCM |
Technical Analysis (APVO)
Nexqual's technical model rates APVO "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 07:49 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.63 (neutral) |
| vs SMA50 | Below (USD 4.82) |
| MACD | 0.01 (positive) |
Analyst Ratings (APVO)
Wall Street analysts rate APVO "Strong Buy" based on 1 analysts, with a mean price target of USD 21 (range USD 21–21), per Nexqual as of June 10, 2026 at 07:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 21 |
| High Target | USD 21 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (APVO)
| EPS Estimate | USD -6.2 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -6.41 vs est -5.6 ▼ miss |
| 2025-09-30 | USD -40.14 vs est -37.62 ▼ miss |
| 2025-06-30 | USD -151.2 vs est -1,497.6 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
Financials & Fundamentals (APVO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -517.92% |
| Debt / Equity | 38.08 |
| Current Ratio | 3.36 |
| Total Cash | $14.53M |
| Total Debt | $4.42M |
| Free Cash Flow | $-17.87M |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
Financial Health Score (APVO)
Nexqual rates Aptevo Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $15M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$27M |
| Efficiency | Critical — ROE -518%, ROA -118.0% |
Ownership (APVO)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +4.45% |
| Shares Outstanding | 1.25M |
| Float | 1.25M |
| Short % of Float | +6.44% |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
Leadership (APVO)
Aptevo Therapeutics Inc. is led by Jeffrey G. Lamothe CA (age 59), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:49 UTC.
| CEO, President & Director | Jeffrey G. Lamothe CA (age 59) |
|---|---|
| Senior VP & CFO | Daphne L. Taylor (age 59) |
| Vice President of Investor Relations & Corporate Communications | Miriam Weber Miller |
| Senior Vice President & Chief Medical Officer | Dirk Huebner (age 62) |
Major Backers & Investors (APVO)
Notable institutional backers of Aptevo Therapeutics Inc. include GSA Capital Partners LLP, Fidelity, UBS Group AG, according to Nexqual as of June 10, 2026 at 07:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GSA Capital Partners LLP | 1.58% |
| Fidelity | 0.83% |
| UBS Group AG | 0.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.37% |
| Geode Capital | 1.07% |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
From Aptevo Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
- The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
- Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.
- It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 2.63% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| KZIA | Kazia Therapeutics Limited | USD 11.42 | ▲ 3.91% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
| ISPC | iSpecimen Inc. | USD 2.92 | ▼ 3.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:49 UTC. This page is informational and not investment advice.